BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 24552141)

  • 21. Gaining insights into relevance across cancers based on mutation features of TP53 gene.
    Mei Y; Liang D; Wang T; Yu D
    Biochem Biophys Rep; 2021 Dec; 28():101165. PubMed ID: 34786492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analysis reveals distinct mutational signature and its mechanistic insights of alcohol consumption in human cancers.
    Wei R; Li P; He F; Wei G; Zhou Z; Su Z; Ni T
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32480415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
    Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
    Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
    Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
    Elife; 2023 Mar; 12():. PubMed ID: 36883553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent somatic mutations reveal new insights into consequences of mutagenic processes in cancer.
    Stobbe MD; Thun GA; Diéguez-Docampo A; Oliva M; Whalley JP; Raineri E; Gut IG
    PLoS Comput Biol; 2019 Nov; 15(11):e1007496. PubMed ID: 31765368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation-based and feature-driven mutation signature analyses to identify genetic features associated with DNA mutagenic processes in cancer genomes.
    Jeong HY; Yoo J; Kim H; Kim TM
    Genomics Inform; 2021 Dec; 19(4):e40. PubMed ID: 35172473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy.
    Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Serizawa M; Maruyama K; Naruoka A; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
    Cancer Sci; 2019 Aug; 110(8):2620-2628. PubMed ID: 31152682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
    Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
    BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of mutational signatures in C. elegans: Implications for cancer genome analysis.
    Meier B; Volkova NV; Gerstung M; Gartner A
    DNA Repair (Amst); 2020 Nov; 95():102957. PubMed ID: 32980770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational processes of tobacco smoking and APOBEC activity generate protein-truncating mutations in cancer genomes.
    Adler N; Bahcheli AT; Cheng KCL; Al-Zahrani KN; Slobodyanyuk M; Pellegrina D; Schramek D; Reimand J
    Sci Adv; 2023 Nov; 9(44):eadh3083. PubMed ID: 37922356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling clinical and molecular covariates of mutational process activity in cancer.
    Robinson W; Sharan R; Leiserson MDM
    Bioinformatics; 2019 Jul; 35(14):i492-i500. PubMed ID: 31510643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and genomic characterization of mutational signatures across human cancers.
    Liao J; Bai J; Pan T; Zou H; Gao Y; Guo J; Xu Q; Xu J; Li Y; Li X
    Int J Cancer; 2023 Apr; 152(8):1613-1629. PubMed ID: 36533638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational signatures efficiently identify different mutational processes underlying cancers with similar somatic mutation spectra.
    Zhou N; Yuan Y; Long X; Wu C; Bao J
    Mutat Res; 2017 Dec; 806():27-30. PubMed ID: 28942182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatic mutation but not aneuploidy differentiates lung cancer in never-smokers and smokers.
    Moorthi S; Paguirigan A; Ko M; Pettinger M; Hoge ACH; Nag A; Patel NA; Wu F; Sather C; Fitzgibbon MP; Thorner AR; Anderson GL; Ha G; Berger AH
    bioRxiv; 2023 Jan; ():. PubMed ID: 36712079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The topography of mutational processes in breast cancer genomes.
    Morganella S; Alexandrov LB; Glodzik D; Zou X; Davies H; Staaf J; Sieuwerts AM; Brinkman AB; Martin S; Ramakrishna M; Butler A; Kim HY; Borg Å; Sotiriou C; Futreal PA; Campbell PJ; Span PN; Van Laere S; Lakhani SR; Eyfjord JE; Thompson AM; Stunnenberg HG; van de Vijver MJ; Martens JW; Børresen-Dale AL; Richardson AL; Kong G; Thomas G; Sale J; Rada C; Stratton MR; Birney E; Nik-Zainal S
    Nat Commun; 2016 May; 7():11383. PubMed ID: 27136393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer.
    Kim YA; Wojtowicz D; Sarto Basso R; Sason I; Robinson W; Hochbaum DS; Leiserson MDM; Sharan R; Vadin F; Przytycka TM
    Genome Med; 2020 May; 12(1):52. PubMed ID: 32471470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational signature SBS8 predominantly arises due to late replication errors in cancer.
    Singh VK; Rastogi A; Hu X; Wang Y; De S
    Commun Biol; 2020 Aug; 3(1):421. PubMed ID: 32747711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
    Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
    Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression.
    Chen YJ; Roumeliotis TI; Chang YH; Chen CT; Han CL; Lin MH; Chen HW; Chang GC; Chang YL; Wu CT; Lin MW; Hsieh MS; Wang YT; Chen YR; Jonassen I; Ghavidel FZ; Lin ZS; Lin KT; Chen CW; Sheu PY; Hung CT; Huang KC; Yang HC; Lin PY; Yen TC; Lin YW; Wang JH; Raghav L; Lin CY; Chen YS; Wu PS; Lai CT; Weng SH; Su KY; Chang WH; Tsai PY; Robles AI; Rodriguez H; Hsiao YJ; Chang WH; Sung TY; Chen JS; Yu SL; Choudhary JS; Chen HY; Yang PC; Chen YJ
    Cell; 2020 Jul; 182(1):226-244.e17. PubMed ID: 32649875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breaking bad: The mutagenic effect of DNA repair.
    Chen J; Furano AV
    DNA Repair (Amst); 2015 Aug; 32():43-51. PubMed ID: 26073774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.